MA-ALIRA-HEALTH
11.5.2022 15:02:07 CEST | Business Wire | Press release
Alira Health (www.alirahealth.com ), a global healthcare advisory and technology company, today announced the acquisition of RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction were not disclosed.
RedCrow was launched in 2016 by Brian Smith, a former Morgan Stanley financial advisor, and Jerry Harrison, an entrepreneur and member of the Rock and Roll Hall of Fame with Talking Heads. RedCrow mines the “wisdom of the crowd” to help find companies that resonate with an audience that may not only use a product but also invest in and realize a return from the company that invented it. This acquisition extends Alira Health’s ability to partner with patients across the lifecycle of drug and device development into the financing phase for early-stage pharma, MedTech, and healthcare services solutions.
“From personal experience, the founders at RedCrow recognize that not every drug or device receives the right investment,” said Gabriele Brambilla, CEO, and founder of Alira Health. “By reinventing and democratizing the way early-stage companies get funded, RedCrow helps more healthcare solutions come to market that can save patients’ lives. Alira Health already partners with patients across the development lifecycle. With RedCrow, we can now involve patients, their care circles, and other investors in the financing phase for new products that may also improve their care outcomes.”
RedCrow’s Brian Smith added, “We founded RedCrow with the belief that healthcare investing should be more immediate, transparent, and accessible, and that patients and their family members should be able to help fund future developments that may impact their own care. We embrace Alira Health’s mission to humanize healthcare and view our platform as a natural extension of Alira Health’s business model. At the same time, early-stage companies on the RedCrow platform can benefit from the breadth of Alira Health’s extensive services offering.”
Since its founding, RedCrow has marketed over 250 fundraises totaling $250 million. Recent success stories include HeartBeam (NASDAQ: BEAT), Sen Jam Pharmaceutical, Activ Surgical and Centerline Biomedical.
About RedCrow
Headquartered in Mill Valley, Calif., RedCrow, which was created because of the 2012 Jobs Act, is a direct investment and marketing platform for healthcare innovation, providing curated deal flow for all investors. RedCrow leverages both the industry experts to provide comprehensive analysis on healthcare startups, enabling a wide array of investors to help healthcare innovation succeed. When a startup joins RedCrow, it's equipped with the tools it needs, like virtual deal rooms, to market its company and investment opportunity. RedCrow leverages the knowledge of its advisory board, which includes financial, scientific, and medical professionals, along with its online community of investors, healthcare professionals, and patients to identify and support innovative companies.
Learn more at https://www.redcrow.com/home/what-we-do.html . Follow RedCrow on Twitter (@RedCrowCrowd) at https://twitter.com/RedCrowCrowd and LinkedIn at https://www.linkedin.com/company/redcrow-crowd/ .
About Alira Health
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.
Learn more at https://alirahealth.com/ . Follow Alira Health on Twitter (@AliraHealth) at https://twitter.com/alirahealth and LinkedIn at https://www.linkedin.com/company/alira-health/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release
Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom